Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...

Major Depressive Disorder, and Persistent Depressive Disorder. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual ...